

Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial

The FUTURE I/II Study Group

Correspondence to: J Dillner, Department of Medical Microbiology, Lund University, Malmö University Hospital, SE-20502 Malmö, Sweden
joakim.dillner@med.lu.se

Cite this as: *BMJ* 2010;340:c3493
doi:10.1136/bmj.c3493

ABSTRACT

Objectives To evaluate the prophylactic efficacy of the human papillomavirus (HPV) quadrivalent vaccine in preventing low grade cervical, vulvar, and vaginal intraepithelial neoplasias and anogenital warts (condyloma acuminata).

Design Data from two international, double blind, placebo controlled, randomised efficacy trials of quadrivalent HPV vaccine (protocol 013 (FUTURE I) and protocol 015 (FUTURE II)). The trials were to be 4 years in length, and the results reported are from final study data of 42 months' follow-up.

Setting Primary care centres and university or hospital associated health centres in 24 countries and territories around the world.

Participants 17 622 women aged 16-26 years enrolled between December 2001 and May 2003. Major exclusion criteria were lifetime number of sexual partners (≥ 4), history of abnormal cervical smear test results, and pregnancy.

Intervention Three doses of quadrivalent HPV vaccine (for serotypes 6, 11, 16, and 18) or placebo at day 1, month 2, and month 6.

Main outcome measures Vaccine efficacy against cervical, vulvar, and vaginal intraepithelial neoplasia grade I and condyloma in a per protocol susceptible population that included subjects who received all three vaccine doses, tested negative for the relevant vaccine HPV types at day 1 and remained negative through month 7, and had no major protocol violations. Intention to treat, generally HPV naive, and unrestricted susceptible populations were also studied.

Results In the per protocol susceptible population, vaccine efficacy against lesions related to the HPV types in the vaccine was 96% for cervical intraepithelial neoplasia grade I (95% confidence interval 91% to 98%), 100% for both vulvar and vaginal intraepithelial neoplasia grade I (95% CIs 74% to 100%, 64% to 100% respectively), and 99% for condyloma (96% to 100%). Vaccine efficacy against any lesion (regardless of HPV type) in the generally naive population was 30% (17% to 41%), 75% (22% to 94%), and 48% (10% to 71%) for cervical, vulvar, and vaginal intraepithelial neoplasia

grade I, respectively, and 83% (74% to 89%) for condyloma.

Conclusions Quadrivalent HPV vaccine provided sustained protection against low grade lesions attributable to vaccine HPV types (6, 11, 16, and 18) and a substantial reduction in the burden of these diseases through 42 months of follow-up.

Trial registrations NCT00092521 and NCT00092534.

INTRODUCTION

Human papillomaviruses (HPVs) are responsible for about 500 000 cases of cervical cancer a year globally¹ and 10 million further cases of high grade cervical intraepithelial neoplasias (grades II or III),² immediate precursors to malignancy. It is estimated that 30 million women and men acquire anogenital warts (condyloma acuminata) or low grade cervical intraepithelial neoplasia each year,² which may be an underestimation given the inadequacy of reporting in many countries and evidence of a rising incidence over time. Although many low grade lesions of the lower genital tract resolve spontaneously in immunocompetent subjects, this type of lesion contributes greatly to the clinical and economic burden of HPV disease in women. The psychosocial^{3 4} and economic^{5 6} implications of condyloma are substantial and reflect, in part, the high transmission rates and inadequacy of available treatment options in achieving prolonged response rates.⁷⁻⁹ Cervical intraepithelial neoplasia grade I can contain a variety of low or high risk HPV types,¹⁰⁻¹² whereas anogenital warts are (in up to 90% of cases) caused by either of two low risk HPV types—namely, 6 and 11.^{9 13 14}

The quadrivalent HPV vaccine (for types 6, 11, 16, and 18) has the potential to prevent about 70% of cervical cancers¹⁵ and 90% of condyloma^{9 13} by targeting HPV types 16 and 18 and types 6 and 11, respectively. Clinical trials have shown that in the per protocol population (that is, subjects naive to a given HPV type(s) at baseline and throughout the three dose vaccination) vaccine efficacy against cervical intraepithelial neoplasia grade II-III or adenocarcinoma in situ was 99% (95% confidence interval 93% to

100%).¹⁶ Efficacy against vulvar and vaginal intraepithelial neoplasia grade II-III was 100% (72% to 100%).¹⁷ High efficacy against condyloma has also been demonstrated (100% (92% to 100%)).¹⁸ These data have led to regulatory approval of the vaccine in roughly 100 countries for the prevention of cervical cancer, cervical cancer precursor lesions, and condyloma in girls and women aged 9-26 years. In some countries, the approved indication also includes vulvar and vaginal cancers.

Details of different patient populations analysed for efficacy of quadrivalent human papillomavirus (HPV) vaccine

Per protocol susceptible population

- Subjects
 - Received all three vaccination doses
 - Were negative for HPV types 6, 11, 16, and 18 at day 1 (by serology and polymerase chain reaction (PCR)) and through month 7 (by PCR)
 - Generally did not deviate from study protocol
- Case counting began after month 7
- Represents an ideal population under ideal study conditions and approximates to a sexually naive population
- Used for analyses of disease related to HPV types 6, 11, 16, and 18

Unrestricted susceptible population

- Subjects
 - Received ≥ 1 vaccination dose
 - Were negative for HPV types 6, 11, 16, and 18 at day 1 (by serology and PCR)
 - Had any follow-up visit
- Case counting began after day 1
- Represents a broader population than per protocol susceptible population, including subjects completing the full three vaccination doses and others who received only one or two doses
- Used for analyses of disease related to HPV types 6, 11, 16, and 18

Generally HPV naive population

- Subjects
 - Received ≥ 1 vaccination
 - Were negative for HPV types 6, 11, 16, and 18 at day 1 (by serology and PCR), negative at day 1 for other high risk HPV types with PCR assays available (31, 33, 35, 39, 45, 51, 52, 56, 58, and 59), and had a negative cervical smear test result on day 1
 - Had any follow-up visit
- Case counting began after day 1
- Represents an approximation of a "real world" population of HPV naive women
- Used for analyses of disease due to any HPV type

Intention to treat population

- Subjects
 - Received ≥ 1 vaccination
 - Had any follow-up visit ($>98\%$ of all subjects enrolled)
- Case counting began after day 1
- Represents a population of women with past and current HPV exposures as well as those presumably naive to HPV
- Used for analyses of disease related to
 - HPV types 6, 11, 16, and 18
 - Any HPV type

The contribution of HPV types 6, 11, 16, and 18 to low grade neoplasias has not been well elucidated. The HPV types have been found in 25-50% of low grade cervical and vulvovaginal neoplasias,¹⁰⁻¹² but assigning causality is difficult because most of these lesions contain multiple HPV types. Whether elimination of some of the HPV types in a multiple infection will prevent disease can be proved only through vaccination. This report represents a combined analysis of quadrivalent HPV vaccine protocols 013 (FUTURE I trial) and 015 (FUTURE II trial), focusing on the efficacy of the vaccine in preventing low grade cervical and vulvovaginal lesions (grade I neoplasias and condyloma) after an average of 42 months of follow-up. We also sought to describe the proportion of the low grade disease burden that can be prevented by vaccination against HPV types 6, 11, 16, and 18.

METHODS

Study designs

Data are considered from two international, double blind, placebo controlled, randomised efficacy trials of the quadrivalent HPV vaccine (protocol 013¹⁸ (FUTURE I, NCT00092521) and protocol 015¹⁹ (FUTURE II, NCT00092534)). These trials were similar in design and infrastructure and were conducted among women aged 16-26 years from North America, Latin America, Europe, and Asia Pacific. Primary efficacy end points assessed in protocol 013 included (a) condyloma, vulvar and vaginal intraepithelial neoplasia, or vulvar and vaginal cancer related to HPV types 6, 11, 16, or 18; and (b) cervical intraepithelial neoplasia, adenocarcinoma in situ, or cervical cancer related to HPV types 6, 11, 16, or 18. The primary efficacy end points assessed in protocol 015 were cervical intraepithelial neoplasia grades II-III and cervical cancer related to HPV types 16 or 18.

Pregnant women and those with a history of >4 lifetime sexual partners or history of an abnormal cervical smear test result were not eligible to participate in these trials. The institutional review board at each participating centre approved the protocol, and informed consent was obtained from all participants. The current report details the complete follow-up data from protocols 013 and 015, representing a mean follow-up period of 42 months.

Vaccine

In each of the studies, eligible subjects were randomised in a 1:1 ratio to receive three doses of the quadrivalent (HPV types 6, 11, 16, and 18) LI virus-like particle vaccine (Gardasil, Merck, Whitehouse Station, NJ, USA) or placebo at day 1, month 2, and month 6 (additional vaccination regimens included as part of protocol 013 did not contribute to the data reported here).

Study procedures

Detailed cervicovaginal examinations were performed at the scheduled day 1 and month 7 visits, including cervical collections for cervical smear testing (Thin-Prep, Cytec Corporation, Boxborough, MA, USA),

Table 1 | Efficacy of quadrivalent human papillomavirus (HPV) vaccine against low grade lesions attributable to vaccine HPV types (6, 11, 16, and 18): analysis of per protocol susceptible population*

Lesion and related HPV type†	Vaccine group		Placebo group		Vaccine efficacy (% (95% CI))	
	No of cases/ No of subjects	Person years at risk	No of cases/ No of subjects	Person years at risk	Unadjusted	Adjusted‡
Cervical intraepithelial neoplasia grade I (HPV 6, 11, 16, 18):	7/7629	22 456.6	168/7632	22 306.3	95.9 (91.3 to 98.4)	95.9 (91.2 to 98.1)
HPV 6 or 11	0/6688	19 756.5	45/6619	19 452.6	100 (91.6 to 100)	100 (NA)
HPV 16	6/6448	19 122.2	97/6257	18 531.1	94.0 (86.5 to 97.9)	93.9 (86.2 to 97.3)
HPV 18	1/7158	21 118.9	47/7092	20 827.4	97.9 (87.7 to 99.9)	97.9 (84.8 to 99.7)
Vulvar intraepithelial neoplasia grade I (HPV 6, 11, 16, 18):	0/7665	23 042.9	16/7669	23 041.1	100 (74.1 to 100)	100 (NA)
HPV 6 or 11	0/6718	20 179.0	16/6647	19 982.8	100 (74.3 to 100)	100 (NA)
HPV 16	0/6455	19 417.0	0/6269	18 859.6	NA	NA
HPV 18	0/7190	21 613.9	0/7119	21 418.9	NA	NA
Vaginal intraepithelial neoplasia grade I (HPV 6, 11, 16, 18):	0/7665	23 042.9	12/7669	23 049.8	100 (64.0 to 100)	100 (NA)
HPV 6 or 11	0/6718	20 179.0	6/6647	19 999.0	100 (15.8 to 100)	100 (NA)
HPV 16	0/6455	19 417.0	7/6269	18 859.6	100 (32.6 to 100)	100 (NA)
HPV 18	0/7190	21 613.9	2/7119	21 418.9	100 (<0 to 100)	100 (NA)
Condyloma (HPV 6, 11, 16, 18):	2/7665	23 039.6	190/7669	22 849.4	99.0 (96.2 to 99.9)	99.0 (95.8 to 99.7)
HPV 6 or 11	2/6718	20 175.7	186/6647	19 798.0	98.9 (96.1 to 99.9)	98.9 (95.7 to 99.7)
HPV 16	0/6455	19 417.0	23/6269	18 839.4	100 (83.1 to 100)	100 (NA)
HPV 18	0/7190	21 613.9	11/7119	21 406.8	100 (60.5 to 100)	100 (NA)

*Per protocol susceptible population=subjects who (a) received all three vaccinations; (b) tested negative for vaccine HPV types at day 1 (by serology and polymerase chain reaction (PCR)) and through month 7 (by PCR); and (c) generally did not deviate from the protocol. Case counting began after month 7.

†A lesion attributable to vaccine HPV types was a diagnosed lesion with DNA from a vaccine HPV type detected in tissue from the same lesion. Cervical biopsies that were performed in the absence of an abnormal cervical smear test result at the antecedent visit were excluded.

‡Adjusted by a Cox model using region and protocol (FUTURE I or FUTURE II) as covariates. Confidence intervals cannot be estimated in Cox models with zero cases in the vaccine group.

comprehensive anogenital inspection, and a series of cervical or anogenital swab collections (that is, endocervical or ectocervical, combined labial-vulvar-perineal, and perianal swabs) for HPV DNA testing. Protocol 013 had an additional scheduled visit at month 3, during which gynaecological examination and cervical or anogenital swab collection occurred (but not serum sampling or cervical smear testing). Cytology specimens were evaluated using the 2001 Bethesda system.²⁰ Colposcopy referral was based on a decision algorithm. Biopsy material was first read for clinical management by pathologists at a central laboratory (Diagnostic Cytology Laboratories, Indianapolis, IN) and then read for end point determination by a blinded panel of four pathologists.

After the three dose vaccination, protocol 013 participants were to return for follow-up assessments every six months (until month 48), whereas protocol 015 participants were seen every 12 months (until month 48). Interim visits were required six months after detection of atypical squamous cells of undetermined significance or low grade squamous intraepithelial lesions to provide the opportunity for repeat cervical smear testing and, if indicated, further colposcopic evaluation and biopsy. If an anogenital lesion was detected, investigators were instructed to obtain specimens representing each affected area and each morphology in a given area. Definitive treatment was based on local standards of care.

Sensitive and specific multiplex polymerase chain reaction assays were used for HPV typing of biopsy samples for HPV 6, 11, 16, 18, and 10 other HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, and 59). For the low grade

analyses reported here, a case required a consensus diagnosis from the pathology panel of cervical, vaginal, or vulvar intraepithelial neoplasia grade I, or condyloma with DNA of HPV types 6, 11, 16, or 18 detected in an adjacent section from the same tissue block.

In 2005 the International Society for the Study of Vulvovaginal Disease changed nomenclature for vulvar intraepithelial neoplasia and categorised it as usual (u-VIN, HPV related) or differentiated (d-VIN, not HPV related) types. The term VIN I was abandoned, and terms VIN II and VIN III were merged.²¹ In this report, however, we have maintained the original nomenclature (VIN I) that was used by the pathology panel during the course of the studies.

Statistical methods

The box lists the criteria and rationale for the analysis populations considered in this report (per protocol susceptible, intention to treat, generally HPV naive, and unrestricted susceptible). The statistical analysis plan specified that determination of the efficacy of the vaccine was to be based on analyses of the per protocol susceptible population; other populations were analysed only for supportive results.

Vaccine efficacy analyses were performed based on low grade lesion type, pooling subjects across the studies by vaccination group (vaccine or placebo). Data were analysed to determine vaccine efficacy against lesions attributable to vaccine HPV types (6, 11, 16, and 18) as well as to any tested HPV type, with the latter analyses including the 10 non-vaccine HPV types for which polymerase chain reaction testing was performed in protocols 013 and 015 (types 31, 33, 35,

Table 2 | Efficacy of quadrivalent human papillomavirus (HPV) vaccine against low grade lesions attributable to vaccine HPV types (6, 11, 16, and 18): analysis of unrestricted susceptible population*

Lesion and related HPV type†	Vaccine group		Placebo group		Vaccine efficacy (% (95% CI))	
	No of cases/ No of subjects	Person years at risk	No of cases/ No of subjects	Person years at risk	Unadjusted	Adjusted‡
Cervical intraepithelial neoplasia grade I (HPV 6, 11, 16, 18):	12/8375	29 081.4	235/8430	29 063.8	94.9 (90.9 to 97.4)	94.9 (90.8 to 97.1)
HPV 6 or 11	2/7420	25 879.5	60/7466	25 870.6	96.7 (87.4 to 99.6)	96.6 (86.2 to 99.2)
HPV 16	6/7113	24 979.5	137/7141	24 944.4	95.6 (90.2 to 98.4)	95.6 (90.1 to 98.1)
HPV 18	4/7906	27 537.1	66/7970	27 622.0	93.9 (83.7 to 98.4)	93.9 (83.4 to 97.8)
Vulvar intraepithelial neoplasia grade I (HPV 6, 11, 16, 18):	2/8497	29 825.1	20/8532	29 995.6	89.9 (58.6 to 98.9)	89.9 (57.0 to 97.6)
HPV 6 or 11	2/7529	26 429.1	18/7553	26 582.1	88.8 (53.3 to 98.7)	88.8 (51.7 to 97.4)
HPV 16	0/7220	25 363.4	2/7222	25 444.7	100 (<0 to 100)	100 (NA)
HPV 18	0/8022	28 179.3	0/8067	28 387.4	NA	NA
Vaginal intraepithelial neoplasia grade I (HPV 6, 11, 16, 18):	0/8497	29 829.3	18/8532	30 000.6	100 (77.1 to 100)	100 (NA)
HPV 6 or 11	0/7529	26 433.3	7/7553	26 600.8	100 (30.2 to 100)	100 (NA)
HPV 16	0/7220	25 363.4	10/7222	25 436.7	100 (55.3 to 100)	100 (NA)
HPV 18	0/8022	28 179.3	5/8067	28 387.4	100 (<0 to 100)	100 (NA)
Condyloma (HPV 6, 11, 16, 18):	10/8497	29 807.5	249/8532	29 692.7	96.0 (92.5 to 98.1)	96.0§ (92.5 to 97.9)
HPV 6 or 11	9/7529	26 414.0	243/7553	26 287.7	96.3 (92.9 to 98.3)	96.3 (92.8 to 98.1)
HPV 16	1/7220	25 360.9	27/7222	25 411.6	96.3 (77.5 to 99.9)	96.2 (72.3 to 99.5)
HPV 18	0/8022	28 179.3	19/8067	28 364.7	100 (78.4 to 100)	100 (NA)

*Unrestricted susceptible population=subjects who (a) received ≥ 1 vaccination; (b) tested negative for vaccine HPV types at day 1 (by serology and polymerase chain reaction); and (c) had any follow-up visit. Case counting began after day 1.

†A lesion attributable to vaccine HPV types was a diagnosed lesion with DNA from a vaccine HPV type detected in tissue from the same lesion. Cervical biopsies that were performed in the absence of an abnormal cervical smear test result at the antecedent visit were excluded.

‡Adjusted by a Cox model using region and protocol (FUTURE I or FUTURE II) as covariates. Confidence intervals cannot be estimated in Cox models with zero cases in the vaccine group.

§Proportional hazard assumption was violated for the treatment effect. The vaccine efficacy was reported as average effect.

39, 45, 51, 52, 56, 58, and 59). Unadjusted vaccine efficacy rates were calculated as $(1 - \text{relative risk}) \times 100$, with corresponding 95% confidence intervals estimated via an exact conditional procedure.²² Relative risk was defined as the ratio of the incidence rate in the vaccine group divided by the incidence rate in the placebo group, using person-time incidence rates.

In order to adjust for study effect and country effect, vaccine efficacy rates were also calculated using a Cox model in which protocol and region were included as cofactors. Regarding the method used for adjusting for study effect and region, we settled for using a Cox regression model because it is more distribution-free (semi-parametric) than Poisson regression. When calculating the vaccine efficacy as $1 - \text{relative risk}$ (that is, $1 - \text{hazard ratio}$, with the Cox model), the only assumption used was that the ratio of hazards is constant over time (but the underlying risks can vary over time). An alternative analysis with Poisson regression (using the PROC GENMOD procedure in the SAS statistical package) gave almost identical results (supplementary table A on bmj.com).

Many of the efficacy end points analysed here and in previous reports are composite, capturing more than one pathological diagnosis or more than one HPV type, or both. Subjects were counted as a single case for a composite end point regardless of whether they met the criteria for only one or for more of its components; however, individual subjects were counted within each of the individual components for which the criteria were met. For example, a subject with both HPV type 6 and type 16 identified in an emergent anogenital wart was counted once within each HPV-specific

analysis but only once in the composite end point of condyloma related to HPV types 6, 11, 16, or 18.

RESULTS

Subject population

A total of 17 599 women aged 16-26 years were randomised and received one or more dose of the quadrivalent HPV vaccine or placebo. Baseline characteristics for the randomised population, which were similar in the vaccine and placebo groups, have been published previously.²³ Overall, mean age at enrolment was 20.0 years, mean age at first sexual intercourse was 16.7 years, non-virgins had a mean of 2.1 lifetime sexual partners, and 11.2% of subjects (1955/17 433) had abnormal cervical cytology at enrolment. The day 1 prevalence for one or more of the HPV types included in the vaccine was 14.7% by polymerase chain reaction (2593/17622) and 19.8% by serology (3482/17 581). A day 1 positive test for DNA of HPV types 6, 11, 16, and 18 was 4.1% (717/17 622), 0.7% (120/17 622), 8.7% (1553/17 622), and 3.6% (641/17 622), respectively. Corresponding day 1 seropositivity was 8.2% (1438/17 567), 2.0% (1036/17 566), 11.3% (1980/17 567), and 3.7% (646/17 566), respectively.

Efficacy in preventing disease related to HPV types 6, 11, 16, or 18

As expected, compared with the per protocol susceptible population (table 1), more cases of low grade cervical or vulvar intraepithelial neoplasia and condyloma were documented in the unrestricted susceptible and intention to treat populations (tables 2 and 3, respectively). Vaccine efficacy in the intention to

Table 3 | Efficacy of quadrivalent human papillomavirus (HPV) vaccine against low grade lesions attributable to vaccine HPV types (6, 11, 16, and 18): analysis of intention to treat population*

Lesion and related HPV type†	Vaccine group		Placebo group		Vaccine efficacy (% (95% CI))	
	No of cases/ No of subjects	Person years at risk	No of cases/ No of subjects	Person years at risk	Unadjusted	Adjusted‡
Cervical intraepithelial neoplasia grade I (HPV 6, 11, 16, 18):	114/8562	29 611.9	366/8598	29 473.1	69.0 (61.6 to 75.1)	68.8§ (61.5 to 74.7)
HPV 6 or 11	19/8562	29 688.6	87/8598	29 648.7	78.2 (63.9 to 87.5)	78.0§ (63.9 to 86.6)
HPV 16	81/8562	29 652.9	240/8598	29 601.6	66.3 (56.5 to 74.1)	66.0§ (56.3 to 73.6)
HPV 18	20/8562	29 701.7	91/8598	29 672.7	78.0 (64.1 to 87.2)	78.1 (64.4 to 86.5)
Vulvar intraepithelial neoplasia grade I (HPV 6, 11, 16, 18):	8/8689	30 472.9	26/8702	30 563.7	69.1 (29.8 to 87.9)	69.1 (31.8 to 86.0)
HPV 6 or 11	8/8689	30 472.9	23/8702	30 570.7	65.1 (19.2 to 86.5)	65.1 (22.0 to 84.4)
HPV 16	0/8689	30 490.8	6/8702	30 602.0	100 (<0 to 100)	100 (NA)
HPV 18	0/8689	30 488.1	0/8702	30 595.8	NA	NA
Vaginal intraepithelial neoplasia grade I (HPV 6, 11, 16, 18):	4/8689	30 479.5	24/8702	30 568.6	83.3 (51.3 to 95.8)	83.3 (52.0 to 94.2)
HPV 6 or 11	2/8689	30 485.4	8/8702	30 599.2	74.9 (<0 to 97.4)	75.0 (<0 to 94.7)
HPV 16	2/8689	30 484.8	14/8702	30 590.1	85.7 (37.6 to 98.4)	85.7 (37.1 to 96.8)
HPV 18	1/8689	30 488.1	6/8702	30 595.8	83.3 (<0 to 99.6)	83.3 (<0 to 98.0)
Condyloma (HPV 6, 11, 16, 18):	63/8689	30 326.2	305/8702	30 137.9	79.5 (73.0 to 84.6)	79.4§ (73.0 to 84.3)
HPV 6 or 11	62/8689	30 328.7	298/8702	30 151.2	79.3 (72.7 to 84.5)	79.2§ (72.7 to 84.2)
HPV 16	3/8689	30 481.8	32/8702	30 564.2	90.6 (70.0 to 98.2)	90.4 (68.6 to 97.1)
HPV 18	1/8689	30 487.1	22/8702	30 571.0	95.4 (71.8 to 99.9)	95.3 (65.1 to 99.4)

*Intention to treat population=subjects who (a) received ≥ 1 vaccination; and (b) had any follow-up visit. Case counting began after day 1.

†A lesion attributable to vaccine HPV types was a diagnosed lesion with DNA from a vaccine HPV type detected in tissue from the same lesion. Cervical biopsies that were performed in the absence of an abnormal cervical smear test result at the antecedent visit were excluded.

‡Adjusted by a Cox model using region and protocol (FUTURE I or FUTURE II) as covariates. Confidence intervals cannot be estimated in Cox models with zero cases in the vaccine group.

§Proportional hazard assumption was violated for the treatment effect. The vaccine efficacy was reported as average effect.

treat and unrestricted susceptible populations was generally lower than observed in the per protocol susceptible population, but it remained statistically significant for all four disease end points, ranging from 90% for vulvar intraepithelial neoplasia (2 cases in vaccine group *v* 20 cases in placebo group) to 100% for vaginal intraepithelial neoplasia (0 *v* 18 cases) in the unrestricted susceptible population (table 2) and from 69% for cervical intraepithelial neoplasia (114 *v* 366 cases) to 83% for vaginal intraepithelial neoplasia (4 *v* 24 cases) in the intention to treat population (table 3). Reductions were also seen in both populations when we evaluated vaccine efficacy against lesions attributable to specific vaccine HPV types (tables 2 and 3).

In the per protocol susceptible population (table 1), seven cases of cervical intraepithelial neoplasia attributable to HPV types 6, 11, 16, or 18 were documented in the vaccine group (n=7629) after month 7 compared with 168 cases in the placebo group (n=7632)—translating into a vaccine efficacy of 96% (95% confidence interval 91% to 98%). Stratified by HPV type, vaccine efficacy rates against cervical intraepithelial neoplasia remained statistically significant and ranged from 94% for HPV 16 to 100% for HPV 6 or 11 (table 1). With no cases of vulvar or vaginal intraepithelial neoplasia attributable to vaccine HPV types (6, 11, 16, or 18) in the vaccine group compared with 16 cases and 12 cases, respectively, in the placebo group (n=7669), vaccine efficacy was 100% in preventing these low grade neoplasias. All of the emergent vulvar cases in the placebo group were attributable to HPV types 6 or 11, whereas all four vaccine HPV types were identified among the vaginal lesions. There were two cases of condyloma

attributable to vaccine HPV types among vaccine recipients (n=7665) versus 190 cases among placebo recipients (n=7669)—a vaccine efficacy of 99% (96% to 100%). HPV type 6 was documented in both of the cases of condyloma in the vaccine group, and HPV types 6 or 11 were found in 98% of the placebo cases (186/190). Table 4 summarises the cases of lesions attributable to vaccine HPV types among vaccine recipients in the per protocol susceptible population.

Efficacy in preventing disease due to any HPV type

Vaccine efficacy against any cervical intraepithelial neoplasia grade I (regardless of HPV types present) was 30% (17% to 41%) in the generally HPV naive population (241 cases in vaccine group *v* 346 in placebo group) and 20% (12% to 28%) in the intention to treat population (788 *v* 984 cases) (table 5). In the generally HPV naive population, vaccine efficacy against any vulvar intraepithelial neoplasia grade I, vaginal intraepithelial neoplasia grade I, or condyloma was 75% (22% to 94%) (4 *v* 16 cases), 48% (10% to 71%) (21 *v* 41 cases), and 83% (74% to 89%) (29 *v* 169 cases) respectively (table 5). Corresponding efficacy in the intention to treat population was 32% (<0 to 60%) (27 *v* 40 cases), 31% (4% to 51%) (62 *v* 90 cases), and 62% (54% to 69%) (134 *v* 351 cases), respectively (table 5).

DISCUSSION

We found that vaccination with quadrivalent HPV vaccine had a high prophylactic efficacy against low grade cervical and vulvovaginal neoplasias and condyloma attributed to HPV types 6, 11, 16, and 18 through 42 months of follow-up. This report confirms the

Table 4 | Description of cases of low grade lesions attributable to human papillomavirus (HPV) types 6, 11, 16, or 18 among women in the per protocol susceptible population receiving quadrivalent HPV vaccine

Case*	Age (years)	Baseline HPV positivity†	Detected	Vaccine HPV type found	Patient narrative
Cervical intraepithelial neoplasia grade I					
1	17	None	Month 13	HPV 16	Colposcopy yielded two tissue specimens (both CIN grade I). Both biopsies were positive for HPV 58, one was positive for HPV 16.
2	20	None	Month 13	HPV 16	Colposcopy yielded two tissue specimens, one of which was CIN grade I positive for HPV 16
3	22	HPV 18, 31, 33, 39	Month 11	HPV 16	Colposcopy yielded tissue specimen (read as CIN grade III) positive for HPV 18, 31, 33, and 39. Definitive therapy by LEEP yielded seven biopsies, only one of which was positive for HPV 16 (also positive for HPV 18, 33, and 39) and diagnosed as CIN grade I
4	23	HPV 39	Month 13	HPV 16	Colposcopy yielded two tissue specimens, one was normal and one was CIN grade I positive for HPV 16
5	22	HPV 56	Month 35	HPV 18	Colposcopy tissue specimen read as CIN grade II (positive for HPV 56, negative for HPV 18). Three LEEP specimens were diagnosed as CIN grade I (all positive for HPV 56, and 1 positive for HPV 18)
Condyloma					
6	18	None	Month 8	HPV 6	
7	16	None	Month 36	HPV 6	Condyloma positive for HPV 6 and 59

CIN=cervical intraepithelial neoplasia. LEEP=loop electrosurgical excision procedure.

*Narratives not available for two women who developed cervical intraepithelial neoplasia grade I.

†A positive test for DNA of HPV types 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, or 59.

results of previous studies with shorter follow-up times and increases the statistical power of the efficacy estimates (via longer follow-up) and provides evidence of longer duration of protection. There were no signs of waning protection.

Putting these data in context

The reported efficacy against low grade HPV related lesions is important for several reasons. Firstly, these lesions occur shortly after infection, and a reduction in these lesions will be the earliest clinically noticeable health gain to be realised by HPV vaccination. The incubation time for condyloma is on average about three months, and a decline in these readily apparent lesions is an early monitoring end point for confirming that HPV vaccination programmes have had an important effect at the population level. Monitoring for outbreaks with re-emergence of condylomas has been proposed as an integral part of HPV surveillance programmes after vaccination.

Secondly, condyloma and cervical intraepithelial neoplasia grade I occur at substantially higher rates than cervical intraepithelial neoplasia grade II/III, and the absolute number of these cases prevented by vaccination is expected to be large when vaccine coverage is high. Thus, short term benefits of HPV vaccination in sexually active populations lie in the reduction of condylomas and cervical intraepithelial neoplasia grade I.

Thirdly, the fact that infection with multiple HPV types is common in low grade disease, particularly in cervical intraepithelial neoplasia but also in condyloma, has made it difficult to unequivocally assign which of the HPV types present in a lesion are the causal infections. Our data therefore provide important confirmatory evidence of the proportion of low grade disease positive for HPV types 6, 11, 16, or 18 (37% (366/984) of cervical intraepithelial neoplasia grade I, 87% (305/351) of condyloma (tables 3 and 5, intention to treat placebo groups)). As expected, the proportion

of disease prevented in generally naive subjects was similar but slightly lower than the proportion of cases found to contain the DNA of these viruses (30% of cervical intraepithelial neoplasia grade I, 83% of condyloma). Co-infection with a non-vaccine HPV type can result in uncertainty in assigning causality, as shown by the substantial proportion of the cases of disease in the vaccine group that were also positive for a non-vaccine HPV type (3/7 cases of cervical intraepithelial neoplasia grade I and 1/2 cases of condyloma in the per protocol population). In several cases the additional HPV type had been detected at the baseline visit and persisted through the study.

Low grade cervical and vulvovaginal lesions are important from a public health perspective, as the diagnosis, follow-up, and treatment of these common lesions are associated with substantial patient anxiety, morbidity, and healthcare costs.^{10,24} The lifetime risk of a clinically diagnosed condyloma has in Scandinavia been estimated to be >10%.²⁵ Management of cervical intraepithelial neoplasia grade I and condyloma therefore contributes to a large proportion of the overall financial burden of HPV related disease.²⁶

Condyloma and HPV vaccination

The incidence of condyloma and the potential for health gains by HPV vaccination has hitherto not been well described. Although condyloma reporting systems are used in a few countries, these systems have not been sufficiently well controlled to allow reliable estimates of incidence. In this study we measured vaccine efficacy against disease related to specific HPV type and against disease regardless of HPV type, enabling an estimate of the total gains in reduced disease burden after vaccination of generally HPV naive women. In addition, our report provides an estimate of the incidence of these lesions in a carefully monitored cohort of women. We found a high incidence of condyloma in the placebo group (169 cases), which translates into a yearly incidence of 1.0%. The vaccine efficacy against condyloma

Table 5 | Efficacy of quadrivalent human papillomavirus (HPV) vaccine against low grade lesions attributable to any HPV type

	No of cases/No of subjects		Vaccine efficacy (% (95% CI))	
	Vaccine group	Placebo group	Unadjusted	Adjusted*
Generally HPV naive population†				
Cervical intraepithelial neoplasia grade I	241/4616	346/4680	29.7 (16.9 to 40.6)	29.9 (17.3 to 40.5)
Vulvar intraepithelial neoplasia grade I	4/4689	16/4735	74.7 (21.5 to 93.8)	74.6 (23.9 to 91.5)
Vaginal intraepithelial neoplasia grade I	21/4689	41/4735	48.1 (10.2 to 70.9)	49.2 (14.0 to 70.0)
Condyloma	29/4689	169/4735	82.8 (74.3 to 88.8)	82.8 (74.5 to 88.4)
Intention to treat population‡				
Cervical intraepithelial neoplasia grade I	788/8562	984/8598	20.3 (12.4 to 27.5)	20.0 (12.1 to 27.2)
Vulvar intraepithelial neoplasia grade I	27/8689	40/8702	32.3 (<0 to 60.0)	32.1 (<0 to 58.4)
Vaginal intraepithelial neoplasia grade I	62/8689	90/8702	30.9 (3.5 to 50.8)	31.2 (4.9 to 50.2)
Condyloma	134/8689	351/8702	62.0 (53.5 to 69.1)	61.9§ (53.5 to 68.8)

*Vaccine efficacy was adjusted by a Cox model using region and protocol (FUTURE I and FUTURE II) as covariates.

†Generally HPV naive population=subjects who (a) received ≥ 1 vaccination; (b) tested negative at day 1 for vaccine HPV types (6, 11, 16, and 18) by serology and polymerase chain reaction (PCR) and for non-vaccine, high risk HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) by PCR and had a negative cervical smear test on day 1; and (c) had any follow-up visit. Case counting began after day 1.

‡Intention to treat population=subjects who (a) received ≥ 1 vaccination; and (b) had any follow-up visit. Case counting began after day 1.

§Proportional hazard assumption was violated for the treatment effect. The vaccine efficacy was reported as average effect.

in generally HPV naive women of 83% thus corresponds to a potential reduction in absolute yearly incidence of condyloma of 0.83%.

In accordance with previous reports, we found oncogenic HPV types such as HPV 16 and 18 in a proportion of condylomas, but usually in conjunction with the major HPV types associated with condyloma (types 6 and 11). Of the 190 cases of condyloma in the per protocol placebo group, 23 were associated with HPV type 16, and 11 associated with HPV type 18. However, HPV types 6 or 11, or both, were also present in all but four of these. Therefore, it seems likely that the quadrivalent vaccine's efficacy against condyloma is primarily attributable to the HPV types 6 and 11 components of the vaccine.

For cervical intraepithelial neoplasia grade I, HPV type 16 was found in about twice as many cases (97/6257) as HPV type 18 (47/7092) and types 6 or 11 (45/6619). As multiple infection with several vaccine types was not common, it seems reasonable to assume that the vaccine's HPV types 6 and 11 component contributed to about a quarter of the protective effect—that is, about 7%–8% of all cervical intraepithelial neoplasia grade I. Thus, the proportion of disease preventable by vaccination against HPV types 6 and 11 was slightly lower than the prevalence of types 6 or 11 in low grade cervical and vulvovaginal disease (estimated at about 10% for cervical intraepithelial neoplasia grade I, 42% for vulvar intraepithelial neoplasia grade I, and 90% for condyloma^{10 12 27 28}). This observation may possibly be related to the occasional cases that may be caused by co-infection with non-vaccine HPV types.

For vulvar intraepithelial neoplasia grade I, our data support the International Society for the Study of Vulvovaginal Disease recommendation to rename this as a “flat wart,” as all cases of vulvar intraepithelial neoplasia grade I were found to harbour HPV types 6 or 11 and thus had similar aetiology as other condylomas. For vaginal intraepithelial neoplasia grade I, about equal numbers of cases were infected with HPV types 6 or 11 as with HPV 16, but small numbers preclude more

exact estimation of the proportion of the protective effect against vaginal intraepithelial neoplasia that was attributable to the HPV 6 and 11 component of the vaccine. Regardless of whether vulvar or vaginal intraepithelial neoplasia grade I are classified as precancerous or as benign warts, patients presenting with low grade vulvar or vaginal lesions still require clinical follow-up and, in some cases, medical or surgical intervention.

Study limitations

Limitations of the current analyses include the fact that the generally HPV naive population was tested only for the presence of the four vaccine HPV types and 10 other HPV types prevalent in cervical cancer. However, other HPV types may contribute to condylomas, and there are several uncommon HPV types that we did not test for (such as HPV 68 and 73) that are classified as oncogenic. Failure to identify infections with these types at baseline would have resulted in an underestimation of the protective effect against any disease in the generally naive population. As these types are not common, this conservative bias is not likely to be substantial. Another limitation concerns the fact that rate estimates of disease are dependent on the intensity of assessment. There were some differences in assessment between studies, notably the fact that protocol 015 required cervical smear screening every 12 months, whereas protocol 013 required smear testing every six months. Although the studies eligibility criteria included a limit on the lifetime number of sexual partners, the generalisability of the results is probably high as the population studied was enrolled globally.

Conclusions and policy implications

Quadrivalent HPV vaccination provided strong and sustained protection for up to four years against condyloma and low grade cervical and vulvovaginal neoplasia related to HPV types 6, 11, 16, and 18. The high incidence of low grade disease seen in the placebo group and the estimated benefits of vaccination on total disease burden regardless of HPV type suggest

WHAT IS ALREADY KNOWN ON THIS TOPIC?

Human papillomaviruses (HPVs) are responsible for substantially more cases of condyloma and cervical intraepithelial neoplasia grade I than cervical intraepithelial neoplasia grade II-III, and the absolute number of these cases prevented by HPV vaccination is expected to be large

The total disease burden of low grade lesions that is preventable by quadrivalent HPV vaccine has not been well elucidated

WHAT DOES THIS STUDY ADD?

Quadrivalent vaccine (for HPV types 6, 11, 16, and 18) provides strong and sustained protection for up to four years against condyloma and low grade cervical and vulvovaginal neoplasia related to these four HPV types

In generally HPV naive subjects, vaccination reduced the total burden of condyloma by 83% and the total burden of cervical intraepithelial neoplasia grade I by 30%

The HPV types 6 and 11 component of the vaccine contributed to about a quarter of the protective effect against cervical intraepithelial neoplasia grade I related to any HPV type in the intention to treat population

that an important portion of the clinical benefit seen in the early years after deployment of the quadrivalent HPV vaccine will be through reductions of cervical intraepithelial neoplasia grade I and condyloma.

We thank Mary Anne Rutlowski and Carolyn Maass for statistical programming support, and Laurie Orloski for writing support. Members of the FUTURE/II Study Group who are authors of this paper: Joakim Dillner,¹ Susanne K Kjaer,² Cosette M Wheeler,³ Kristján Sigurdsson,⁴ Ole-Erik Iversen,⁵ Mauricio Hernandez-Avila,⁶ Gonzalo Perez,⁷ Darron R Brown,⁸ Laura A Koutsky,⁹ Eng Hseon Tay,¹⁰ Patricia García,¹¹ Kevin A Ault,¹² Suzanne M Garland,¹³ Sepp Leodolter,¹⁴ Sven-Eric Olsson,¹⁵ Grace WK Tang,¹⁶ Daron G Ferris,¹⁷ Jorma Paavonen,¹⁸ Matti Lehtinen,¹⁹ Marc Steben,²⁰ F Xavier Bosch,²¹ Elmar A Joura,¹⁴ Slawomir Majewski,²² Nubia Muñoz,²³ Evan R Myers,²⁴ Luisa L Villa,²⁵ Frank J Taddeo,²⁶ Christine Roberts,²⁶ Amha Tadesse,²⁶ Janine T Bryan,²⁶ Roger Maansson,²⁶ Shuang Lu,²⁶ Scott Vuocolo,²⁶ Teresa M Hesley,²⁶ Eliav Barr,²⁶ Richard Haupt,²⁶

Affiliations: ¹Department of Laboratory Medicine, Lund University, Malmö, Sweden, and Departments of Laboratory Medicine, Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; ²Department of Virus, Hormones and Cancer, Institute of Cancer Epidemiology, Danish Cancer Society/Rigshospitalet, Copenhagen, Denmark; ³Departments of Molecular Genetics and Microbiology and Obstetrics and Gynecology, University of New Mexico, Albuquerque NM, USA; ⁴National Cancer Detection Clinic, Reykjavik, Iceland; ⁵Department of Clinical Medicine, University of Bergen and Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway; ⁶Institute of Public Health, Cuernavaca, Morelos, Mexico; ⁷Universidad del Rosario, Bogotá, Colombia; ⁸Department of Medicine, Indiana University School of Medicine, Indianapolis IN, USA; ⁹Department of Epidemiology, University of Washington, Seattle WA, USA; ¹⁰KK Women's and Children's Hospital, Singapore; ¹¹Epidemiology HIV and STD Unit, Universidad Peruana Cayetano Heredia, Lima Peru; ¹²Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA, USA; ¹³Microbiology and Infectious Diseases Department, Royal Women's Hospital and Department of Obstetrics and Gynecology, University of Melbourne, Melbourne, Victoria, Australia; ¹⁴Department of Gynecology and Obstetrics, Medical University of Vienna, Vienna, Austria; ¹⁵Karolinska Institute at Danderyd Hospital, Stockholm, Sweden; ¹⁶Department of Obstetrics and Gynecology, University of Hong Kong, HKSAR; ¹⁷Department of Family Medicine and Obstetrics and Gynecology, Medical College of Georgia, Augusta, GA, USA; ¹⁸Department of Obstetric and Gynecology, University Central Hospital, Helsinki, Finland; ¹⁹School of Public Health, University of Tampere, Tampere, Finland; ²⁰Direction Risques Biologiques, Environnementaux et Occupationnels, Institut National de Santé Publique du Québec, Montréal, Canada; ²¹Institut Catala d'Oncologia, IDIBELL, Barcelona, Spain; ²²Department of Dermatology and Venereology, Center of Diagnostics and Treatment of Sexually Transmitted Diseases, Warsaw Medical University, Warsaw, Poland; ²³National Institute of Cancer, Bogotá, Colombia; ²⁴Department of

Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, USA; ²⁵Department of Virology, Ludwig Institute for Cancer Research, Sao Paulo, Brazil; ²⁶Merck Research Laboratories, West Point, PA, USA

Contributors: EB, RH, and TMH managed the sponsor's operations. JD, CMW, KS, O-EI, MH-A, DRB, LAK, EHT, PG, KAA, SMG, SLE, S-EO, GWKT, DGF, JP, ML, MS, EAJ, GP, and SM set up study sites and enrolled participants into the studies. SKK, GP, NM, FXB, ERM, and LLV helped draft the protocols. JTB, FJT, CR, and AT managed the development of the PCR based assays for HPV types 6, 11, 16, and 18 as well as the execution of genital swab and biopsy sample testing using the assays. RM and SLU provided statistical expertise. JD and SV drafted the manuscript, to which all others contributed and approved before submission.

Funding: Merck Research Laboratories, a division of Merck & Company, funded these studies.

Role of the funding source: The studies were designed by the sponsor (Merck & Company) in collaboration with external investigators and an external data and safety monitoring board. The sponsor collated the data, monitored the conduct of the study, performed the statistical analysis, and coordinated the writing of the manuscript with all authors. The authors were actively involved in the collection, analysis, or interpretation of the data, the revising of the manuscript for intellectual content, and approved the final manuscript.

Competing interests: JD has received consultancy fees, lecture fees, and research grants from Merck & Company and Sanofi Pasteur MSD. SKK has received consultancy fees and has received funding through her institution to conduct HPV vaccine studies for Sanofi Pasteur MSD and Digene. SMG has received advisory board fees and grant support from Commonwealth Serum Laboratories and GlaxoSmithKline, lecture fees from Merck & Company, and funding through her institution to conduct HPV vaccine studies for GlaxoSmithKline. CMW has received funding through her institution to conduct HPV vaccine studies for GlaxoSmithKline, and has received reagents and equipment from Roche Molecular Systems for HPV genotyping studies. KS has received consultancy fees from Merck & Company. O-EI has received lecture fees from Merck & Company and GlaxoSmithKline. LLV has received lecture fees, advisory board fees, and consultancy fees from Merck & Company and Sanofi Pasteur MSD. KAA has received consultancy and advisory board fees. MH-A has received lecture fees and grant support from Merck & Company. GP has received lecture fees and consultancy fees from Merck & Company and Sanofi Pasteur MSD. DRB has received lecture fees, advisory board fees, and intellectual property fees. SLE has received lecture fees from Merck & Company and Sanofi Pasteur MSD. S-EO has received lecture fees from Merck & Company. DGF has received consultancy fees and funding through his institution to conduct HPV vaccine studies for GlaxoSmithKline, and lecture fees and consultancy fees from Merck & Company. JP has received consultancy fees, advisory board fees, and lecture fees from Merck & Company. MS has received lecture fees and grant support from Merck & Company. FXB has received lecture fees from Merck & Company and GlaxoSmithKline, and has received funding through his institution to conduct HPV vaccine studies for GlaxoSmithKline. EAJ has received lecture fees from Merck & Company, Sanofi Pasteur MSD, and GlaxoSmithKline. SM has received lecture fees, advisory board fees, and consultancy fees from Merck & Company and Sanofi Pasteur MSD. NM has received lecture fees, advisory board fees, and consultancy fees from Merck & Company and Sanofi Pasteur MSD. Additionally, S-EO, CMW, MH-A, LLV, O-EI, GWKT, FXB, JP, JD, EHT, SLE, EAJ, SKK, GP, DGF, KS, MS, LAK, and DRB have received funding through their institutions to conduct HPV vaccine studies for Merck & Company. FJT, CR, AT, JTB, RM, SV, TMH, RH, and EB are employees of Merck & Company and potentially own stock or stock options in the company.

Ethical approval: Studies were conducted in conformity with country or local requirements regarding ethics committee review, informed consent, and other statutes or regulations regarding the rights and welfare of human subjects participating in biomedical research.

Data sharing: Data sets are available from the corresponding author at joakim.dillner@med.lu.se.

- 1 Ferlay J, Bray F, Pisani P, Parkin DM. *GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide*. IARC CancerBase No 5, version 2.0. IARC Press, 2004
- 2 World Health Organization. *Human papillomavirus infection and cervical cancer*. 2004. www.who.int/vaccine_research/diseases/hpv/en/.

- 3 Clarke P, Ebel C, Catotti DN, Stewart S. The psychosocial impact of human papillomavirus infection: implications for health care providers. *Int J STD AIDS* 1996;7:197-200.
- 4 Maw RD, Reitano M, Roy M. An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle. *Int J STD AIDS* 1998;9:571-8.
- 5 Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. *Clin Infect Dis* 2003;36:1397-403.
- 6 Langley PC, White DJ, Drake SM. The costs of treating external genital warts in England and Wales: a treatment pattern analysis. *Int J STD AIDS* 2004;15:501-8.
- 7 Kodner CM, Nasrati S. Management of genital warts. *Am Fam Physician* 2004;70:2335-42.
- 8 Lacey CJ. Therapy for genital human papillomavirus-related disease. *J Clin Virol* 2005;32:S82-S90.
- 9 Wiley DJ, Douglas J, Beutner K, Cox T, Fife K, Moscicki AB, et al. External genital warts: diagnosis, treatment and prevention. *Clin Infect Dis* 2002;35:S210-S224.
- 10 Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. *Cancer Epidemiol Biomarkers Prev* 2005;14:1157-64.
- 11 Herrero R, Castle PE, Schiffman M, Bratti MC, Hildesheim A, Morales J, et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. *J Infect Dis* 2005;191:1796-807.
- 12 Srodon M, Stoler MH, Baber GB, Kurman RJ. The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and ValN). *Am J Surg Pathol* 2006;30:1513-8.
- 13 Von Krogh G. Management of anogenital warts (condylomata acuminata). *Eur J Dermatol* 2001;11:598-604.
- 14 Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. *J Infect Dis* 2009;199:805-14.
- 15 Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. *N Engl J Med* 2003;348:518-27.
- 16 The FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3 and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. *Lancet* 2007;369:1861-8.
- 17 Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16 and 18) L1 virus-like-particle vaccine against high-grade vulvar and vaginal lesions: a combined analysis of three clinical trials. *Lancet* 2007;369:1693-702.
- 18 Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. *N Engl J Med* 2007;356:1928-43.
- 19 The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. *N Engl J Med* 2007;356:1915-27.
- 20 Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. *JAMA* 2002;287:2114-9.
- 21 Sideri M, Jones RW, Wilkinson EJ, Preti M, Heller DS, Scurry J, et al. Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee. *J Reprod Med* 2005;50:807-10.
- 22 Chan ISF, Bohidar NR. Exact power and sample size for vaccine efficacy studies. *Theory Meth* 1998;27:1305-22.
- 23 The FUTURE II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virologic evidence of HPV infection. *J Infect Dis* 2007;196:1438-46.
- 24 Insinga RP, Glass AG, Rush BB. The health care costs of cervical human papillomavirus-related disease. *Am J Obstet Gynecol* 2004;191:114-20.
- 25 Kjaer SK, Tran TN, Sparen P, Tryggevadottir L, Munk C, Dasbach E, et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. *J Infect Dis* 2007;196:1447-54.
- 26 Bergeron C, Breugelmans JG, Bouee S, Lorans C, Benard S, Remy V. [Cervical cancer screening and associated treatment costs in France.] *Gynecol Obstet Fertil* 2006;34:1036-42.
- 27 Jansen KU, Shaw AR. Human papillomavirus vaccines and prevention of cervical cancer. *Annu Rev Med* 2004;55:319-31.
- 28 Greer CE, Wheeler CM, Ladner MB, Beutner K, Coyne MY, Liang H, et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. *J Clin Microbiol* 1995;33:2058-63.

Accepted: 29 April 2010